Want to see BNTX full AI Analyst Report?
Revenue by Segment
Shows how much revenue comes from each business line—vaccine sales and partner arrangements (notably revenues tied to the COVID-19 vaccine and Pfizer collaboration), oncology and other therapeutic programs, licensing and collaboration income, and services. Helps investors see whether growth depends on a single product or partner, how much revenue is recurring versus one‑time, and which segments offer sustainable long‑term upside or face regulatory, competitive, or demand risks.Revenue remains highly concentrated and lumpy: Covid‑19 Vaccine drove massive, front‑loaded sales in 2021–22 and still produces intermittent quarter-sized spikes tied to procurement cycles, but baseline receipts have collapsed by 2026; "Other" is increasingly volatile with large one-off uplifts in Q3 2024 and especially Q3 2025, suggesting milestone/partner payments rather than sustainable product revenue. For investors this means earnings and cash will be unpredictable absent durable new product revenue or recurring contracts—be cautious valuing growth without clear repeatability.
Date | Other | Covid-19 Vaccine |
|---|---|---|
Jun 30, 2026 | €53.70M | €51.90M |
Mar 31, 2026 | €51.20M | €66.90M |
Dec 31, 2025 | €51.70M | €855.70M |
Sep 30, 2025 | €665.60M | €853.30M |
Jun 30, 2025 | €107.50M | €153.30M |
Mar 31, 2025 | €49.80M | €133.00M |
Dec 31, 2024 | €67.90M | €1.12B |
Sep 30, 2024 | €130.90M | €1.11B |
Jun 30, 2024 | €56.80M | €71.90M |
Mar 31, 2024 | €63.40M | €124.20M |